Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05162066
Other study ID # BCX9930-211
Secondary ID 2020-005855-19
Status Terminated
Phase Phase 2
First received
Last updated
Start date February 18, 2022
Est. completion date September 23, 2022

Study information

Verified date April 2024
Source BioCryst Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study was to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date September 23, 2022
Est. primary completion date September 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Body weight = 40 kilograms (kg) - Primary diagnosis of C3G, IgAN, or PMN confirmed by central pathology review - An estimated glomerular filtration rate (eGFR) = 50 milliter per minute per 1.73 meter square (mL/min/1.73 m^2) (or = 30 mL/min/1.73 m^2 after Data Monitoring Committee [DMC] recommendation) - Receiving treatment with a stable, maximum recommended or maximum tolerated dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 60 days prior to the Day 1 Visit - Documentation of current vaccinations against Neisseria meningitidis and Streptococcus pneumoniae or willingness to start vaccination series Exclusion Criteria: - Known congenital deficiency of C1s, C1r, C1q, C2, or C4 - History of hematopoietic cell transplant or solid organ transplant or anticipated candidate for transplantation - Myocardial infarction or cerebrovascular accident within 30 days prior to screening, or current and uncontrolled clinically significant cardiovascular or cerebrovascular condition - History of malignancy within 5 years prior to the screening visit - Active serious bacterial, viral, or fungal infection or any other serious infection within 14 days of screening - Treatment with any systemic immunosuppressive or immunomodulatory therapy within 90 days OR anti-CD20 antibody therapies (eg, rituximab) within 180 days prior to the screening visit - Treatment with renin inhibitors (eg, aliskiren) or sodium-glucose-cotransporter 2 (SGLT2) inhibitors within 60 days prior to Day 1

Study Design


Intervention

Drug:
BCX9930
Administered orally at a dose of 200 mg twice daily for the first 2 weeks, then 400 mg twice daily

Locations

Country Name City State
France Investigative Site Poitiers
France Investigative Site Toulouse
Italy Investigative Site Bari
Italy Investigative Site Bergamo
Italy Investigative Site Brescia
Italy Investigative Site Turin
Spain Investigative Site #1 Barcelona
Spain Investigative Site #2 Barcelona
Spain Investigative Site #1 Madrid
Spain Investigative Site #2 Madrid
United Kingdom Investigative Site Oxford

Sponsors (1)

Lead Sponsor Collaborator
BioCryst Pharmaceuticals

Countries where clinical trial is conducted

France,  Italy,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent Change From Baseline in 24-hour uPCR at Week 12 Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. Baseline, Week 12
Primary Percent Change From Baseline in 24-hour uPCR at Week 24 Urinary protein/creatinine ratio (mg/mmol) =urine protein concentration (mg/dL)/ urine creatinine concentration (mmol/dL). Decrease of urinary protein/creatinine ratio means improvement of renal disease. Baseline, Week 24
Secondary Percent Change From Baseline in 24-hour Urinary Protein Excretion Baseline, Weeks 12, 24,
Secondary Change From Baseline in Estimated Glomerular Filtration Rate eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for participants = 18 years old and by the bedside Schwartz formula for participants = 18 years old. eGFR was reported in milliliter per minute per 1.73 per square meter (mL/min/1.73m^2). Baseline, Weeks 12, 24
Secondary Number of Participants With a Treatment-emergent Adverse Event (TEAE) An Adverse event (AE) was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. From first dose up to safety follow-up period (Week 28)
Secondary Number of Participants Who Discontinued Due to a TEAE An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug. From first dose up to safety follow-up period (Week 28)
Secondary Number of Participants Who Experienced a Treatment-emergent Serious Adverse Event (TESAE) An AE was any untoward medical occurrence in a clinical study participant. TEAEs were defined, within a dosing group, as AEs that started on or after the first dose of study treatment through 30 days after the last dose of study drug.
A serious adverse event (SAE) was an adverse event/reaction that results in any of the following outcomes:
Death
Is life-threatening (participant was at immediate risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe)
Requires participant hospitalization (formal admission to a hospital for medical reasons) or prolongation of existing hospitalization
Results in persistent or significant disability/incapacity (ie, there was a substantial disruption of a person's ability to carry out normal life functions)
Is a congenital anomaly/birth defect
From first dose up to safety follow-up period (Week 28)
Secondary Number of Participants Who Experienced a Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4 TEAE An AE was any untoward medical occurrence has no causal relationship with the study drug or with the clinical study itself. It was an unfavorable & unintended sign, symptom, syndrome, or illness that developed or worsened during clinical study.
TEAEs: AEs that started on or after first dose of treatment through 30 days after the last dose of study drug. All AEs were graded using the CTCAE Grades 1 through 5.
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL
Grade 4: Life-threatening consequences; urgent intervention indicated
Grade 5: Death
Participants with Grades 3 or 4 AEs were reported
From first dose up to safety follow-up period (Week 28)
Secondary Number of Participants Who Experienced a CTCAE Treatment-emergent Grade 3 or 4 Laboratory Abnormality Treatment-emergent Laboratory Abnormality were defined as an event that started on or after the first dose of study treatment through 30 days after the last dose of study drug.
CTCAE Grades for laboratory abnormalities include:
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL.
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Death
Participants with Grades 3 or 4 laboratory abnormality were reported.
From first dose up to safety follow-up period (Week 28)
See also
  Status Clinical Trial Phase
Recruiting NCT04095156 - Autoreactive B Cells in Membranous Nephropathy
Not yet recruiting NCT06341205 - Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) Phase 3
Active, not recruiting NCT04893096 - MOR202 for Refractory MN Phase 2
Completed NCT00405340 - Rituximab in the Treatment of Idiopathic Membranous Nephropathy Phase 0
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Active, not recruiting NCT04652570 - Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy Phase 1/Phase 2
Not yet recruiting NCT06242327 - An Outcome Analysis of Primary Membranous Nephropathy
Recruiting NCT03929887 - KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Active, not recruiting NCT03949855 - Belimumab With Rituximab for Primary Membranous Nephropathy Phase 2
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT03025828 - Adrenocorticotropic Hormone in Membranous Nephropathy Phase 4
Recruiting NCT05732402 - An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases Phase 1/Phase 2
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Active, not recruiting NCT05894512 - Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
Not yet recruiting NCT05941845 - Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Phase 2
Completed NCT00518219 - To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Phase 4
Completed NCT02199145 - Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy N/A
Not yet recruiting NCT04326218 - Immunopathological Analysis in a French National Cohort of Membranous Nephropathy N/A
Active, not recruiting NCT03453619 - Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Phase 2
Completed NCT01955187 - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Phase 3